ONWARD MEDICAL BV EO -12 (63E) - Net Assets
Based on the latest financial reports, ONWARD MEDICAL BV EO -12 (63E) has net assets worth €55.32 Million EUR (≈ $64.67 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€84.55 Million ≈ $98.85 Million USD) and total liabilities (€29.24 Million ≈ $34.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ONWARD MEDICAL BV EO -12 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €55.32 Million |
| % of Total Assets | 65.42% |
| Annual Growth Rate | -9.56% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 90.12 |
ONWARD MEDICAL BV EO -12 - Net Assets Trend (2021–2025)
This chart illustrates how ONWARD MEDICAL BV EO -12's net assets have evolved over time, based on quarterly financial data. Also explore total assets of ONWARD MEDICAL BV EO -12 for the complete picture of this company's asset base.
Annual Net Assets for ONWARD MEDICAL BV EO -12 (2021–2025)
The table below shows the annual net assets of ONWARD MEDICAL BV EO -12 from 2021 to 2025. For live valuation and market cap data, see ONWARD MEDICAL BV EO -12 (63E) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €55.32 Million ≈ $64.67 Million |
+15.11% |
| 2024-12-31 | €48.05 Million ≈ $56.18 Million |
+167.99% |
| 2023-12-31 | €17.93 Million ≈ $20.96 Million |
-65.93% |
| 2022-12-31 | €52.63 Million ≈ $61.53 Million |
-36.35% |
| 2021-12-31 | €82.68 Million ≈ $96.67 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ONWARD MEDICAL BV EO -12's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14658400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €277.87 Million | 502.34% |
| Total Equity | €55.32 Million | 100.00% |
ONWARD MEDICAL BV EO -12 Competitors by Market Cap
The table below lists competitors of ONWARD MEDICAL BV EO -12 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Virgin Galactic Holdings Inc
NYSE:SPCE
|
$191.60 Million |
|
MPC Münchmeyer Petersen Capital AG
F:MPCK
|
$191.75 Million |
|
Spurcorp
JSE:SUR
|
$191.80 Million |
|
Starpharma Holdings Ltd
AU:SPL
|
$192.10 Million |
|
Newbury Street II Acquisition Corp Class A Ordinary Shares
NASDAQ:NTWO
|
$191.50 Million |
|
Tele2 AB (publ)
ST:TEL2-A
|
$191.50 Million |
|
Vakif Finansal Kiralama AS
IS:VAKFN
|
$191.50 Million |
|
Graphite One Inc
V:GPH
|
$191.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONWARD MEDICAL BV EO -12's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 48,054,000 to 55,316,000, a change of 7,262,000 (15.1%).
- Net loss of 41,787,000 reduced equity.
- New share issuances of 51,187,000 increased equity.
- Other factors decreased equity by 2,138,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-41.79 Million | -75.54% |
| Share Issuances | €51.19 Million | +92.54% |
| Other Changes | €-2.14 Million | -3.87% |
| Total Change | €- | 15.11% |
Book Value vs Market Value Analysis
This analysis compares ONWARD MEDICAL BV EO -12's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.87x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.03x to 2.87x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.74 | €2.84 | x |
| 2022-12-31 | €1.74 | €2.84 | x |
| 2023-12-31 | €0.59 | €2.84 | x |
| 2024-12-31 | €1.08 | €2.84 | x |
| 2025-12-31 | €0.99 | €2.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ONWARD MEDICAL BV EO -12 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -75.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1105.48%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.53x
- Recent ROE (-75.54%) is above the historical average (-91.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -41.50% | 0.00% | 0.00x | 1.27x | €-42.58 Million |
| 2022 | -62.27% | -31511.54% | 0.00x | 1.46x | €-38.04 Million |
| 2023 | -201.78% | -53207.35% | 0.00x | 2.43x | €-37.97 Million |
| 2024 | -74.34% | -15600.44% | 0.00x | 1.58x | €-40.53 Million |
| 2025 | -75.54% | -1105.48% | 0.04x | 1.53x | €-47.32 Million |
Industry Comparison
This section compares ONWARD MEDICAL BV EO -12's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,132,095,555
- Average return on equity (ROE) among peers: -68.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONWARD MEDICAL BV EO -12 (63E) | €55.32 Million | -41.50% | 0.53x | $191.55 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $242.58 Million | -85.63% | 0.52x | $204.16 Million |
| PreveCeutical Medical Inc (18H) | $-2.29 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.05 Billion | -15.51% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
| BioNTech SE (22UA) | $19.22 Billion | -5.91% | 0.14x | $20.05 Billion |
About ONWARD MEDICAL BV EO -12
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more